78 related articles for article (PubMed ID: 7478545)
1. A novel insertional mutation in the TC21 gene activates its transforming activity in a human leiomyosarcoma cell line.
Huang Y; Saez R; Chao L; Santos E; Aaronson SA; Chan AM
Oncogene; 1995 Oct; 11(7):1255-60. PubMed ID: 7478545
[TBL] [Abstract][Full Text] [Related]
2. Oncogenic activation of human R-ras by point mutations analogous to those of prototype H-ras oncogenes.
Saez R; Chan AM; Miki T; Aaronson SA
Oncogene; 1994 Oct; 9(10):2977-82. PubMed ID: 8084601
[TBL] [Abstract][Full Text] [Related]
3. The TC21 oncoprotein interacts with the Ral guanosine nucleotide dissociation factor.
López-Barahona M; Bustelo XR; Barbacid M
Oncogene; 1996 Feb; 12(3):463-70. PubMed ID: 8637701
[TBL] [Abstract][Full Text] [Related]
4. Identification and characterization of R-ras3: a novel member of the RAS gene family with a non-ubiquitous pattern of tissue distribution.
Kimmelman A; Tolkacheva T; Lorenzi MV; Osada M; Chan AM
Oncogene; 1997 Nov; 15(22):2675-85. PubMed ID: 9400994
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of the Ras-related TC21/R-Ras2 protein may contribute to the development of human breast cancers.
Clark GJ; Kinch MS; Gilmer TM; Burridge K; Der CJ
Oncogene; 1996 Jan; 12(1):169-76. PubMed ID: 8552388
[TBL] [Abstract][Full Text] [Related]
6. TC21 and Ras share indistinguishable transforming and differentiating activities.
Graham SM; Oldham SM; Martin CB; Drugan JK; Zohn IE; Campbell S; Der CJ
Oncogene; 1999 Mar; 18(12):2107-16. PubMed ID: 10321735
[TBL] [Abstract][Full Text] [Related]
7. Farnesyltransferase inhibitors are inhibitors of Ras but not R-Ras2/TC21, transformation.
Carboni JM; Yan N; Cox AD; Bustelo X; Graham SM; Lynch MJ; Weinmann R; Seizinger BR; Der CJ; Barbacid M
Oncogene; 1995 May; 10(10):1905-13. PubMed ID: 7761092
[TBL] [Abstract][Full Text] [Related]
8. Signal transduction elements of TC21, an oncogenic member of the R-Ras subfamily of GTP-binding proteins.
Movilla N; Crespo P; Bustelo XR
Oncogene; 1999 Oct; 18(43):5860-9. PubMed ID: 10557073
[TBL] [Abstract][Full Text] [Related]
9. Ras-related TC21 is activated by mutation in a breast cancer cell line, but infrequently in breast carcinomas in vivo.
Barker KT; Crompton MR
Br J Cancer; 1998 Aug; 78(3):296-300. PubMed ID: 9703274
[TBL] [Abstract][Full Text] [Related]
10. Novel small GTPase M-Ras participates in reorganization of actin cytoskeleton.
Matsumoto K; Asano T; Endo T
Oncogene; 1997 Nov; 15(20):2409-17. PubMed ID: 9395237
[TBL] [Abstract][Full Text] [Related]
11. Oncogenic insertional mutations in the P-loop of Ras are overactive in MAP kinase signaling.
Klockow B; Ahmadian MR; Block C; Wittinghofer A
Oncogene; 2000 Nov; 19(47):5367-76. PubMed ID: 11103938
[TBL] [Abstract][Full Text] [Related]
12. Aberrant function of the Ras-related protein TC21/R-Ras2 triggers malignant transformation.
Graham SM; Cox AD; Drivas G; Rush MG; D'Eustachio P; Der CJ
Mol Cell Biol; 1994 Jun; 14(6):4108-15. PubMed ID: 8196649
[TBL] [Abstract][Full Text] [Related]
13. Rig is a novel Ras-related protein and potential neural tumor suppressor.
Ellis CA; Vos MD; Howell H; Vallecorsa T; Fults DW; Clark GJ
Proc Natl Acad Sci U S A; 2002 Jul; 99(15):9876-81. PubMed ID: 12107278
[TBL] [Abstract][Full Text] [Related]
14. Coamplification in tumors of KRAS2, type 2 inositol 1,4,5 triphosphate receptor gene, and a novel human gene, KRAG.
Heighway J; Betticher DC; Hoban PR; Altermatt HJ; Cowen R
Genomics; 1996 Jul; 35(1):207-14. PubMed ID: 8661122
[TBL] [Abstract][Full Text] [Related]
15. Transformation suppressor activity of C3G is independent of its CDC25-homology domain.
Guerrero C; Fernandez-Medarde A; Rojas JM; Font de Mora J; Esteban LM; Santos E
Oncogene; 1998 Feb; 16(5):613-24. PubMed ID: 9482107
[TBL] [Abstract][Full Text] [Related]
16. Isolation of a gene encoding a developmentally regulated T cell-specific protein with a guanine nucleotide triphosphate-binding motif.
Carlow DA; Marth J; Clark-Lewis I; Teh HS
J Immunol; 1995 Feb; 154(4):1724-34. PubMed ID: 7836757
[TBL] [Abstract][Full Text] [Related]
17. A polymorphism in the TC21 promoter associates with an unfavorable tamoxifen treatment outcome in breast cancer.
Rokavec M; Schroth W; Amaral SM; Fritz P; Antoniadou L; Glavac D; Simon W; Schwab M; Eichelbaum M; Brauch H
Cancer Res; 2008 Dec; 68(23):9799-808. PubMed ID: 19047159
[TBL] [Abstract][Full Text] [Related]
18. Expression cDNA cloning of a novel oncogene with sequence similarity to regulators of small GTP-binding proteins.
Chan AM; McGovern ES; Catalano G; Fleming TP; Miki T
Oncogene; 1994 Apr; 9(4):1057-63. PubMed ID: 8134109
[TBL] [Abstract][Full Text] [Related]
19. Characterization of a human MSX-2 cDNA and its fragment isolated as a transformation suppressor gene against v-Ki-ras oncogene.
Takahashi C; Akiyama N; Matsuzaki T; Takai S; Kitayama H; Noda M
Oncogene; 1996 May; 12(10):2137-46. PubMed ID: 8668339
[TBL] [Abstract][Full Text] [Related]
20. Biological activity of human N-ras and K-ras genes containing the Asn17 dominant negative mutation.
Kaplan JB
Oncol Res; 1994; 6(12):611-5. PubMed ID: 7787254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
